Valuation: Scancell Holdings plc

Market Cap 120M 161M 140M 131M 227M 15.35B 229M 1.54B 602M 7.67B 606M 593M 25.42B P/E 2026 *
-6.62x
P/E 2027 * -12.5x
Enterprise Value 130M 175M 152M 142M 247M 16.68B 249M 1.67B 654M 8.34B 659M 644M 27.63B EV / Sales 2026 *
104x
EV / Sales 2027 * 56.6x
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -
1 week-0.50%
Current month+1.54%
1 month-30.53%
3 months-34.44%
6 months-25.28%
1 week 9.6
Extreme 9.6
10
1 month 9.3
Extreme 9.3
15.5
Current year 9.3
Extreme 9.3
29.5
1 year 7.86
Extreme 7.8555
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 69 28/07/2021
Chief Executive Officer 64 18/11/2024
Director of Finance/CFO 50 24/04/2026
Director TitleAgeSince
Director/Board Member 69 17/11/2010
Director/Board Member 74 23/10/2019
Director/Board Member 64 24/09/2020
Date Insider Type Main position Quantity % Market Cap.
16/9/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
8/8/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
4/8/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.50%-10.00%-5.71% 161M
-0.68%-0.68%-1.63%+12.86% 48.22B
+6.03%+5.22%+420.33%+519.87% 38.79B
-2.21%-6.07%+24.87%+5.20% 38.41B
+2.94%-2.25%+6.15%+59.69% 34.88B
+1.98%+4.74%+12.19%+41.37% 29.19B
+0.47%-3.87% - - 16.05B
+0.31%+0.72%+32.99%+122.25% 16B
+1.59%+0.44%+3.43%+16.80% 13.53B
-0.98%-12.98%-4.82%-38.09% 12.22B
Average +0.94%-0.04%+53.72%+81.58% 24.75B
Weighted average by Cap. +1.21%+1.55%+78.93%+112.32%

Financials

2026 *2027 *
Net sales 1.25M 1.68M 1.46M 1.36M 2.36M 160M 2.39M 16.04M 6.27M 79.92M 6.31M 6.17M 265M 2.4M 3.23M 2.8M 2.61M 4.54M 307M 4.59M 30.8M 12.04M 153M 12.12M 11.85M 508M
Net income -19.23M -25.86M -22.46M -20.94M -36.38M -2.46B -36.78M -247M -96.5M -1.23B -97.12M -94.99M -4.07B -8.24M -11.08M -9.62M -8.97M -15.58M -1.05B -15.75M -106M -41.32M -527M -41.59M -40.68M -1.74B
Net Debt 10.42M 14.01M 12.16M 11.34M 19.7M 1.33B 19.92M 134M 52.26M 666M 52.6M 51.44M 2.21B 15.87M 21.34M 18.53M 17.28M 30.02M 2.03B 30.35M 204M 79.64M 1.01B 80.15M 78.4M 3.36B
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
04/08/26 GBX 9.900 0.00% 4,826,456
03/08/26 GBX 9.900 +1.54% 5,500,747
31/07/26 GBX 9.750 -0.51% 2,099,398
30/07/26 GBX 9.800 -1.01% 3,936,750
29/07/26 GBX 9.900 -0.50% 2,718,058
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0990GBP
Average target price
0.2550GBP
Spread / Average Target
+157.58%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLP Stock